Cardiovascular Disease in AIDS

  • Giuseppe Barbaro
  • Franck Boccara

Table of contents

  1. Front Matter
    Pages I-XVIII
  2. G. Di Perri, S. Audagnotto, F. Gobbi, L. Trentini, A. Calcagno, S. Bonora
    Pages 1-13
  3. S. Ederhy, C. Meuleman, N. Haddour, G. Dufaitre, F. Boccara, A. Cohen
    Pages 75-84
  4. M. Mary-Krause, D. Costagliola
    Pages 99-110
  5. F. Boccara, C. Meuleman, S. Ederhy, S. Lang, S. Janower, A. Cohen et al.
    Pages 111-129
  6. G. Barbaro
    Pages 157-167
  7. N. Bonnet, P. Leprince, S. Varnous, I. Gandjbakhch
    Pages 191-202
  8. Back Matter
    Pages 229-245

About this book

Introduction

The introduction of highly active antiretroviral therapy (HAART) has significantly improved the clinical outcome of HIV disease with increased survival rates. However, the introduction of HAART has generated a contrast in the cardiac manifestations of AIDS. In developed countries, we observed an approximate 30% reduction in the prevalence of HIV-associated cardiomyopathy, possibly related to a reduction of opportunistic infections and myocarditis. In developing countries, however, where the availability of HAART is limited and the pathogenic impact of nutritional factors is significant, we observed an approximate 32% increase in the prevalence of HIV-associated cardiomyopathy and a related high mortality rate from congestive heart failure. Additionally, some HAART regimens in developed countries, especially those including protease inhibitors, may cause an iatrogenic metabolic syndrome (HIV-lipodystrophy syndrome) that is associated with an increased risk of cardiovascular disease. At the same time, the relapse of some opportunistic infections, with possible myocardial involvement, in HIV-infected patients receiving HAART, in the context of the recently described immune reconstitution inflammatory syndrome, yielded an intriguing and complex profile of this dual aspect of cardiology in AIDS in the HAART era. In this new edition of Cardiovascular Disease in AIDS, new insights coming from basic and clinical research in the field of HIV-associated cardiovascular disease and antiretroviral therapy are reported, along with the clinical guidelines for a careful stratification of the cardiovascular risk and cardiovascular monitoring of HIV-infected patients receiving HAART. The authors offer a wide overview of the topic for specialists in cardiology and infectious diseases involved in the clinical management of HIV-infected patients.

Keywords

AIDS Epidemiology HIV HIV infection atherosclerosis cardiovascular cardiovascular system coronary artery disease heart hypertension infection physiology prevention vascular disease virus

Editors and affiliations

  • Giuseppe Barbaro
    • 1
  • Franck Boccara
    • 2
  1. 1.Department of Medical Pathophysiology“Sapienza” University of RomeRomeItaly
  2. 2.Department of Cardiology Saint Antoine University HospitalAssistance Publique - Hôpitaux de Paris and Université Pierre et Marie Curie ParisFrance

Bibliographic information

  • DOI https://doi.org/10.1007/978-88-470-0761-1
  • Copyright Information Springer-Verlag Milan 2009
  • Publisher Name Springer, Milano
  • eBook Packages Medicine
  • Print ISBN 978-88-470-0760-4
  • Online ISBN 978-88-470-0761-1
  • About this book